Drug intelligence / Profile preview

Adzyme Plus

Development stage: Unknown
Lead developer: KEN
Modality: Recombinant Proteins and Enzymes, Small Molecules
Administration: Oral

Overview

Adzyme Plus is a marketed generic digestive aid formulation developed and marketed by KEN Pharmaceuticals. It is a combination product typically containing fungal diastase and pepsin. Fungal diastase is a starch-degrading enzyme (alpha-amylase) that facilitates the hydrolysis of complex carbohydrates into simpler sugars like maltose, while pepsin is a proteolytic enzyme that assists in the breakdown of dietary proteins into smaller peptides. This formulation is indicated for the treatment of various digestive disorders, including dyspepsia, indigestion, flatulence, and loss of appetite, particularly when these conditions are associated with enzymatic deficiency or poor dietary habits.

Brand names: Adzyme Plus
Other names: Fungal Diastase + Pepsin

Beyond the preview

Go deeper on Adzyme Plus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Adzyme Plus.

Explore the full profile